1.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, RĂ¼ter B, Burkard U, Osswald A, Foran JM. A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome. Haematologica 2022;107(11):2742-2747; https://doi.org/10.3324/haematol.2021.280500.